How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone  European Urology Supplements  Volume 6, Issue 6, Pages 467-473 (March 2007) DOI: 10.1016/j.eursup.2007.01.012 Copyright © 2007 Terms and Conditions

Fig. 1 The change in American Urological Association (AUA) Symptom Index score for minimally invasive therapies: results of an AUA meta-analysis [1]. European Urology Supplements 2007 6, 467-473DOI: (10.1016/j.eursup.2007.01.012) Copyright © 2007 Terms and Conditions

Fig. 2 Secondary procedures required after minimally invasive therapies versus transurethral resection of the prostate and sham therapies: results of an American Urological Association meta-analysis [1]. European Urology Supplements 2007 6, 467-473DOI: (10.1016/j.eursup.2007.01.012) Copyright © 2007 Terms and Conditions

Fig. 3 The incidence of common progression events at year 4 in the Medical Therapy of Prostatic Symptoms study [7]. European Urology Supplements 2007 6, 467-473DOI: (10.1016/j.eursup.2007.01.012) Copyright © 2007 Terms and Conditions

Fig. 4 An indirect across-study comparison of symptom improvement following treatment with α-blockers, finasteride, and dutasteride [1,7,9–11]. European Urology Supplements 2007 6, 467-473DOI: (10.1016/j.eursup.2007.01.012) Copyright © 2007 Terms and Conditions

Fig. 5 An indirect across-study comparison of long-term change in prostate volume following treatment with α-blockers, finasteride, and dutasteride [7,9–11]. European Urology Supplements 2007 6, 467-473DOI: (10.1016/j.eursup.2007.01.012) Copyright © 2007 Terms and Conditions